Brief: Xeris Biopharma Announces Research Collaboration And Option Agreement With Horizon Therapeutics PLC For Xeriject™ Formulation Of Teprotumumab
23/11/2022 11:11
Nov 23 (Reuters) - Xeris Biopharma Holdings Inc
XERS.O :
* XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND
OPTION
AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™
FORMULATION OF TEPROTUMUMAB
* XERIS BIOPHARMA HOLDINGS INC - XERIS TO DEVELOP AN
ULTRA-CONCENTRATED, READY-TO-USE, SUBCUTANEOUS INJECTION OF
TEPROTUMUMAB
* XERIS BIOPHARMA HOLDINGS INC - SPECIFIC FINANCIAL TERMS OF
AGREEMENT WERE NOT DISCLOSED
Source text for Eikon: ID:nBw3HwC2Wa
Further company coverage: XERS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xeris Biopharma Holdings
See all newsBrief: Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
Lundbeck expresses interest in buying Xeris, Bloomberg News reports (updated)
Xeris Biopharma rises on report of Lundbeck takeover interest